Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 12 2 2018 04 05 136 141 ENDOTHELIN Hossein Heydar Craniomaxillofacial Research center, Tehran University of Medical Sciences, Oral and Maxillofacial Surgery Department, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran Kamran Mansouri Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran Maryam Norooznezhad Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. AND Craniomaxillofacial Research center, Tehran University of Medical Sciences, Oral and Maxillofacial Surgery Department, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran Fatemeh Norooznezhad Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran Abdolreza Mohamadnia Virology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. AND Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran Naghmeh Bahrami Craniomaxillofacial Research center, Tehran University of Medical Sciences, Oral and Maxillofacial Surgery Department, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran 2017 08 11 2018 01 07 Background: Head and neck squamous cell carcinoma (HNSCC) is one most prevalent cancers among worldwide. Aim of this study was to evaluate possible effect of bevacizumab, a vascular endothelial growth (VEGF) factor monoclonal antibody on HNSCC cells in vitro to evaluate angiogenic profile changes. Materials and Methods: HNSCC cells were grown and after that different concentrations of bevacizumab were added in order to evaluate cytotoxic concentration using MTT assay. Then after, the cultured cells in presence of different concentration of bevacizumab were evaluated for gene expression of VEGF, matrix metalloprotease-2 (MMP-2) and MMP-9 using real time polymerase chain reaction (PCR). Moreover, the VEGF expression was evaluated by enzyme-linked immunosorbent assay (ELISA). Results: The concentration at which half cells died (IC59) was calculated 1779 µg/mL and at this concentration, VEGF protein secretion was decreased by over one fold. RT-PCR results showed that MMP2, MMP9 and VEGF decreased by 1, 0.6 and 1.1 folds, respectively. Conclusion: It seems that bevacizumab could be considered as a side therapy for patients with HNSCC due to its potential for inhibition of angiogenic related factors, but further complementary studies are necessary.   https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/851 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/851/625